



Curriculum Vitae

Personal information **Consuelo Mejías Pavón**

Work experience

1. Employer: Evaluation Unit. Division Pharmacovigilance and Pharmacoepidemiology. AEMPS
 - Start date: 032011
 - End date:
 - Position: Pharmacovigilance Assessor
 - Activities:
 - Country: Spain
2. Employer: Research Center on Congenital Anomalies (CIAC)
 - Start date: 061995
 - End date: 022011
 - Position: Medical advisor of the Spanish Teratology Telephone Information Services.
 - Activities:
 - Country: Spain

Education and training

1. Subject: Facultad de Medicina. Univ. Complutense. Madrid. Spain
 - Start date: 1986
 - End date: 1993
 - Qualification: Degree in Medicine and Surgery
 - Organisation:
 - Country: Spain
2. Subject: Alcala de Henares University
 - Start date: 102015
 - End date: 092016
 - Qualification: Pharmacoepidemiology and Pharmacovigilance Master
 - Organisation: Pharmacoepidemiology and Pharmacovigilance
 - Country: Spain

Additional information

Publications

Rodríguez_Pinilla E, Mejias C, Prieto_Merino D, Fernandez P, Martinez_Frias ML Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy _ A case_control study in Spain Drug Safety 2008; 31(6);537:543

Mejias C, Rodríguez_Pinilla E, Martin PF, Martinez_Frias ML Adverse effects of selective serotonin reuptake inhibitors use during the third trimester of pregnancy and prevention guidelines Med Clin (Barc) 2007; 128(15);584:589

Elvira Rodríguez_Pinilla, David Prieto_Merino, Griselda Dequino, Consuelo Mejías , Paloma Fernández, María_Luisa Martínez_Frías. Antenatal exposure to corticosteroids for fetal lung maturation and its repercussion on weight, length and head circumference in the newborn infant. Med Clin (Barc) 2006, 16 Septiembre, 127(10): 361 – 367 Rodríguez Pinilla E, Pavón de Paz MT, Mejías Pavón C y Martínez_Frías ML. Spanish Teratology Telephone Information Service. Med Clin (Barc). 1998 Jun 27;111(3):117_8.

Rodríguez Pinilla E, Mejías Pavón C., Pavón de Paz MT y Martínez_Frías ML: Antimicóticos imidazólicos y embarazo: el fluconazol como un posible nuevo teratógeno. Prog Obstet Ginecol, 42: 359_364, 1999 D. García_Azorín, E. Lázaro, D.

Ezpeleta et al., Síndrome de trombosis con trombocitopenia asociado a vacunas de adenovirus frente a la COVID_19: Epidemiología y presentación clínica de la serie española, Neurología, <https://doi.org/10.1016/j.nrl.2022.04.010>

Projects

FIS (Fondo de Investigación Sanitaria, Spain), Project 97/0111 (1997_1999). "Estudio caso_control del potencial efecto teratogénico de los antibióticos y corticoides en nuestro medio". Principal Investigator: Dr. ML. Martínez_Frías FIS (Fondo de Investigación Sanitaria, Spain). Project 04/2703 (2005_2007) "Utilización de Antidepresivos durante la gestación y sus efectos sobre el desarrollo embrionario/fetal humano". Principal Investigator: Rodríguez Pinilla, E Researcher of CIBERER (Rare Diseases CIBER) From 2007 to 2011. This is one of the nine public consortiums set up at the initiative of the Carlos III Health Institute (ISCIII) to act as a reference, coordinate and foster research into rare diseases in Spain.

Memberships

Other Relevant Information

HSPH-HMS214X: "Fundamentals of Clinical Trials" A course of study offered by HarvardX, an online learning initiative of Harvard University through edX (October 2013-February 2014)

Training Course Assessment of Drug-Induced Liver Injury (DILI): Key rules and common pitfalls. November 2016, AEMPS.

EudraVigilance Data Analysis System, 2016, EMA.

SCOPE Work Package 5 Signal Management, Utrecht, the Netherlands, April 2017

PRAC training for assessors 2017 (ONLINE), November 2017

Concepts in Pharmacoepidemiology (intermediate level), November 2018, AEMPS.

Periodic safety report PSUR and PSUR Single Assessment (PSUSA), ONLINE, EU Network Training Centre.

Course: F2F_ Pharmacovigilance assessments_challenges and solutions for pharmacovigilance assessors 2019 organized by EMA in 11_12th November 2019. Length 17 hours.

PRAC Training for assessors 2022: Pharmacovigilance assessments-challenges and solutions for pharmacovigilance assessors. November 2022. Length 8.5 hours